Yonkenafil

• Description :

  Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease[1].

• CAS Number :

  [804518-63-6]

• Product Name Alternative :

  Tunodafil

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/yonkenafil.html

• Purity :

  99.52

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1C2=C(N(CCC)C=C2C)N=C(C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC)N1

• Molecular Formula :

  C24H33N5O4S

• Molecular Weight :

  487.61

• Precautions :

  P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

• References & Citations :

  [1]Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1